Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

18675 results about "In vivo" patented technology

Studies that are in vivo (Latin for "within the living"; often not italicized in English) are those in which the effects of various biological entities are tested on whole, living organisms or cells, usually animals, including humans, and plants, as opposed to a tissue extract or dead organism. This is not to be confused with experiments done in vitro ("within the glass"), i.e., in a laboratory environment using test tubes, Petri dishes, etc. Examples of investigations in vivo include: the pathogenesis of disease by comparing the effects of bacterial infection with the effects of purified bacterial toxins; the development of non-antibiotics, antiviral drugs, and new drugs generally; and new surgical procedures. Consequently, animal testing and clinical trials are major elements of in vivo research. In vivo testing is often employed over in vitro because it is better suited for observing the overall effects of an experiment on a living subject. In drug discovery, for example, verification of efficacy in vivo is crucial, because in vitro assays can sometimes yield misleading results with drug candidate molecules that are irrelevant in vivo (e.g., because such molecules cannot reach their site of in vivo action, for example as a result of rapid catabolism in the liver).

Electrochemical analyte sensor

An electrochemical analyte sensor having conductive traces on a substrate is used to determine a level of analyte in in vitro or in vivo analyte-containing fluids. The electrochemical analyte sensor includes a substrate and conductive material disposed on the substrate, the conductive material forming a working electrode. In some sensors, the conductive material is disposed in recessed channels formed in a surface of the sensor. An electron transfer agent and / or catalyst may be provided to facilitate the electrolysis of the analyte or of a second compound whose level depends on the level of the analyte. A potential is formed between the working electrode and a reference electrode or counter / reference electrode and the resulting current is a function of the concentration of the analyte in the fluid.
Owner:ABBOTT DIABETES CARE INC

Subcutaneous glucose electrode

A small diameter flexible electrode designed for subcutaneous in vivo amperometric monitoring of glucose is described. The electrode is designed to allow “one-point” in vivo calibration, i.e., to have zero output current at zero glucose concentration, even in the presence of other electroreactive species of serum or blood. The electrode is preferably three or four-layered, with the layers serially deposited within a recess upon the tip of a polyamide insulated gold wire. A first glucose concentration-to-current transducing layer is overcoated with an electrically insulating and glucose flux limiting layer (second layer) on which, optionally, an immobilized interference-eliminating horseradish peroxidase based film is deposited (third layer). An outer (fourth) layer is biocompatible.
Owner:THERASENSE

Biointerface membranes incorporating bioactive agents

A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is provided. The bioactive agents can be chosen to induce vascularization and / or prevent barrier cell layer formation in vivo, and are advantageous when used with implantable devices wherein solutes are transported across the device-tissue interface.
Owner:DEXCOM

Implantable analyte sensor

InactiveUS20050245799A1Improved patient convenienceConvenient careCatheterDiagnostic recording/measuringAnalyteMiniaturization
Abstract of the DisclosureAn implantable analyte sensor including a sensing region for measuring the analyte and a non-sensing region for immobilizing the sensor body in the host. The sensor is implanted in a precisely dimensioned pocket to stabilize the analyte sensor in vivo and enable measurement of the concentration of the analyte in the host before and after formation of a foreign body capsule around the sensor. The sensor further provides a transmitter for RF transmission through the sensor body, electronic circuitry, and a power source optimized for long-term use in the miniaturized sensor body.
Owner:DEXCOM

Self-supporting, shaped, three-dimensional biopolymeric materials and methods

Self-supporting, shaped, three-dimensional cross-linked proteinaceous biopolymeric materials that may be implanted in vivo, and methods of making such materials are disclosed. The biopolymeric materials most preferably include reinforcing media, such as biocompatible fibrous or particulate materials. In use, the preformed, shaped biopolymeric materials may be applied to tissue in need of repair and then sealed around its edges with a liquid bioadhesive. In such a manner, repaired tissue which is capable of withstanding physiological pressures may be provided.
Owner:CRYOLIFE

Implantable analyte sensor

Abstract of the DisclosureAn implantable analyte sensor including a sensing region for measuring the analyte and a non-sensing region for immobilizing the sensor body in the host. The sensor is implanted in a precisely dimensioned pocket to stabilize the analyte sensor in vivo and enable measurement of the concentration of the analyte in the host before and after formation of a foreign body capsule around the sensor. The sensor further provides a transmitter for RF transmission through the sensor body, electronic circuitry, and a power source optimized for long-term use in the miniaturized sensor body.
Owner:DEXCOM

Analyte measuring device

An implantable analyte-measuring device including a membrane adapted to promote vascularization and / or interfere with barrier cell layer formation. The membrane includes any combination of materials, architecture, and bioactive agents that facilitate analyte transport to provide long-term in vivo performance of the implantable analyte-measuring device.
Owner:DEXCOM

Optical-based sensing devices

An optical-based sensor for detecting the presence or amount of an analyte using both indicator and reference channels. The sensor has a sensor body with a source of radiation embedded therein. Radiation emitted by the source interacts with indicator membrane indicator molecules proximate the surface of the body. At least one optical characteristic of these indicator molecules varies with analyte concentration. For example, the level of fluorescence of fluorescent indicator molecules or the amount of light absorbed by light-absorbing indicator molecules can vary as a function of analyte concentration. In addition, radiation emitted by the source also interacts with reference membrane indicator molecules proximate the surface of the body. Radiation (e.g., light) emitted or reflected by these indicator molecules enters and is internally reflected in the sensor body. Photosensitive elements within the sensor body generate both indicator channel and reference channel signals to provide an accurate indication of the concentration of the analyte. Preferred embodiments are totally self-contained and are sized and shaped for use in vivo in a human being. Such embodiments preferably include a power source, e.g. an inductor, which powers the source of radiation using external means, as well as a transmitter, e.g. an inductor, to transmit to external pickup means the signal representing the level of analyte.
Owner:SENSEONICS INC

Methods for generating polynucleotides having desired characteristics by iterative selection and recombination

A method for DNA reassembly after random fragmentation, and its application to mutagenesis of nucleic acid sequences by in vitro or in vivo recombination is described. In particular, a method for the production of nucleic acid fragments or polynucleotides encoding mutant proteins is described. The present invention also relates to a method of repeated cycles of mutagenesis, shuffling and selection which allow for the directed molecular evolution in vitro or in vivo of proteins.
Owner:CODEXIS MAYFLOWER HLDG LLC

Device and system for in-vivo procedures

A system for performing in vivo procedures is provided. The system may include a tool for performing an in vivo procedure. The tool may have an in vivo sensor for obtaining in vivo information; a functional element for performing an interventional or diagnostic in-vivo procedure; a processor in communication with the tool for receiving and optionally processing the in vivo information obtained by the tool and a monitor in communication with the processor for displaying the optionally processed in vivo information. The communication between the elements of the system may be wireless, or, optionally, wired.
Owner:GILREATH MARK G +1

Human antibodies that bind human IL-12 and methods for producing

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
Owner:ABBVIE DEUTSHLAND GMBH & CO KG

Continuous cardiac marker sensor system

The present invention relates generally to systems and methods for continuous measurement of a cardiac marker in vivo. In some embodiments, the system includes a continuous sensor and a communication device. The continuous sensor is configured to continuously measure a concentration of a cardiac marker in vivo and to provide a signal associated therewith. The communication device includes a processor module configured to process the signal to obtain cardiac information, wherein the communication device is configured to output the cardiac information.
Owner:DEXCOM

Continuous medicament sensor system for in vivo use

Systems and methods for continuous measurement of a medicament in vivo are provided. In some embodiments, the system is configured to provide information associated with medicament titration and includes a continuous analyte sensor and a communication device. In some embodiments, the system is configured for continuous ambulatory drug testing, including an ambulatory host monitor having a continuous sensor, a location module, a processor module and a transmitter. In some embodiments, the system is configured for continuously monitoring a hormone level and includes a continuous hormone sensor and a communication device configured to output hormone information in real time. Yet another embodiment provides an analyte sensor for continuous monitoring of a host's nutritional status, and is configured for both continuous glucose detection and continuous albumin detection.
Owner:DEXCOM

Flexible sensor apparatus

ActiveUS20070073129A1Quick and easy transcutaneous placementImprove stabilitySurgical needlesCatheterAnalyteAdhesive
A flexible mounting base to hold a sensor at an infusion site, the sensor being a removable in vivo sensor for monitoring analyte concentration level in a patient, such as blood glucose (BG) level. The mounting base comprises a flexible adhesive that anchors the flexible sensor set at an infusion site to provide stability for the sensor set in a convenient and comfortable manner. Placement of the mounting base onto the patient's skin causes the insertion needle to pierce the skin for transcutaneous placement of the cannula with the sensor therein. The insertion needle can then be withdrawn to leave the cannula and sensor at the selected insertion position, with the distal segment of the sensor being exposed to patient extracellular fluid via apertures formed in the cannula.
Owner:MEDTRONIC MIMIMED INC

Systems for in vivo site-directed mutagenesis using oligonucleotides

This disclosure provides several methods to generate nucleic acid mutations in vivo, for instance in such a way that no heterologous sequence is retained after the mutagenesis is complete. The methods employ integrative recombinant oligonucleotides (IROs). Specific examples of the described mutagenesis methods enable site-specific point mutations, deletions, and insertions. Also provided are methods that enable multiple rounds of mutation and random mutagenesis in a localized region. The described methods are applicable to any organism that has a homologous recombination system.
Owner:HEALTH & HUMAN SERVICES DEPT OF THE GOVERNMENT OF THE US SEC THE

Low oxygen in vivo analyte sensor

The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous and subcutaneous measurement of glucose in a host.
Owner:DEXCOM

Methods for generating polynucleotides having desired characteristics by iterative selection and recombination

A method for DNA reassembly after random fragmentation, and its application to mutagenesis of nucleic acid sequences by in vitro or in vivo recombination is described. In particular, a method for the production of nucleic acid fragments or polynucleotides encoding mutant proteins is described. The present invention also relates to a method of repeated cycles of mutagenesis, shuffling and selection which allow for the directed molecular evolution in vitro or in vivo of proteins.
Owner:CODEXIS MAYFLOWER HLDG LLC

In vivo biosensor apparatus and method of use

InactiveUS6673596B1Less can be administeredCost-effective administration of drugBioreactor/fermenter combinationsBiological substance pretreatmentsIn vivoGenetically engineered
Disclosed are bioluminescent bioreporter integrated circuit devices that detect selected analytes in fluids when implanted in the body of an animal. The device comprises a bioreporter that has been genetically engineered to contain a nucleic acid segment that comprises a cis-activating response element that is responsive to the selected substance operably linked to a gene encoding a bioluminescent reporter polypeptide. In preferred embodiments, the target analyte is glucose, glucagons, or insulin. Exposure of the bioreporter to the target substance causes the response element to up-regulate the nucleic acid sequence encoding the reporter polypeptide to produce a luminescent response that is detected and quantitated. In illustrative embodiments, the bioreporter device is encapsulated on an integrated circuit that is capable of detecting the emitted light, processing the resultant signal, and then remotely reporting the results. Also disclosed are controlled drug delivery systems capable of being directly or indirectly controlled by the detection device that provide drugs such as insulin to the animal in reponse to the amount of target analyte present in the body fluids.
Owner:UNIV OF TENNESSEE RES FOUND +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products